Treatment with imatinib mesylate, a potent ABL-specific tyrosine kinase inhibitor (TKI), has shown remarkable clinical activity in a majority of CML patients in chronic phase, but in fewer patients in accelerated and blast phase [1]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.